An Encouraging Quarter, Ironwood One to Keep on the Radar in 2014
Research - Ironwood (IRWD) had a good quarter, and the next few quarters should look even better as an advertising campaign kicks off.
Read nowSearch Results for plecanatide
On the Bio Sector: Get Comfortable in the Unknown
Insights - What do you do in a choppy environment? Know what you own, why, and try to get comfortable.
Read nowWhat We’re Trading, What We’re Stalking
Recap - Shares of Tekmira Pharmaceuticals (TKMR) have been on an absolute tear. Already since our January 7th reiteration to PropThink Premium members to own the stock, TKMR is up a … Continue Reading
Read now
Linzess Sales Ramp Reads Positive for Synergy Pharma
Research - Ironwood Pharmaceuticals (IRWD) reported financial results for the fourth quarter and full year 2013 on Tuesday morning. We’re interested primarily for the read-through on Synergy Pharmaceuticals … Continue Reading
Read nowRecapping Our Week in the Healthcare Sector
Recap - Mr. Deryugin started off the week updating the thesis on antibiotic developer Cubist Pharmaceuticals (CBST), which acquired Trius Therapeutics (TSRX) and Optimer Pharmaceuticals (OPTR) in 2013. Cubist missed … Continue Reading
Read nowAnother Week of Healthcare Trading at PropThink: Here’s the Recap
Most Popular - Sunshine Heart (SSH), in its first ever quarterly conference call on Wednesday, provided more anecdotal evidence that its C-Pulse device is benefitting late-stage heart failure … Continue Reading
Read nowPositive for Ironwood is Positive for Synergy
Long Ideas - Ironwood Pharmaceuticals (IRWD) reported 2Q earnings on Tuesday morning, trouncing analyst estimates for sales of Linzess and assuaging a major overhang on the stock. The … Continue Reading
Read now